Sigilon Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGTX research report →
Price Chart
About the company
Cambridge, Massachusetts-based Sigilon Therapeutics, Inc. , established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A.
- CEO
- Rogerio Vivaldi Coelho MBA
- IPO
- 2020
- Employees
- 62
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on SGTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $56.22M
- P/E
- -16.77
- PEG
- -0.05
- P/S
- 4.34
- P/B
- 18.60
- EV/EBITDA
- -1.09
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -337.35%
- Net Margin
- -335.72%
- ROE
- -74.73%
- ROIC
- -64.60%
Latest fiscal year · YoY change
- Revenue
- $12.94M+34.8%
- Gross Profit
- $12.94M+34.8%
- Op Income
- $-43,666,000
- Net Income
- $-43,456,000+44.5%
- EPS
- $-1.34+95.8%
- OCF Growth
- +34.3%
- FCF Growth
- +35.2%
- 52W High
- $28.00
- 52W Low
- $3.77
- 50D MA
- $14.79
- 200D MA
- $9.81
- Beta
- 4.11
- RSI (14)
- 71
- Avg Volume
- 120.68K
No earnings-call transcripts are available for SGTX yet.
- Free Float
- 0.0%
- Shares Outstanding
- 2.50M
- Float Shares
- 0
of shares held by institutions
30 13F filers
Buy/sell ratio 0.11. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Amalgamated Financial Corp. | 1.96K | ▲ 1.96K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 23 | Flagship Ventures Fund V General Partner LLC | other | 113,960 |
| Aug 11, 23 | ELI LILLY & Co | buy | 1,718,493 |
| Aug 11, 23 | Cole Douglas G. | sell | 683 |
| Aug 11, 23 | Cole Douglas G. | sell | 683 |
| Aug 11, 23 | Oesterle Stephen N. | sell | 4,273 |
| Aug 11, 23 | Oesterle Stephen N. | sell | 683 |
| Aug 11, 23 | Oesterle Stephen N. | sell | 683 |
| Aug 11, 23 | Shaff Eric D. | sell | 683 |
| Aug 11, 23 | Shaff Eric D. | sell | 683 |
| Aug 11, 23 | RUFFOLO ROBERT R | sell | 683 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SGTX coverage
Recent articles, reports, and earnings notes.
No research on SGTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SGTX report →Lilly Completes Acquisition of Sigilon Therapeutics
prnewswire.com · Aug 14
SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX
businesswire.com · Jul 21
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
zacks.com · Jun 30
Eli Lilly to buy Sigilon Therapeutics on a massive premium
invezz.com · Jun 29
Eli Lilly to Acquire Sigilon Therapeutics
investopedia.com · Jun 29
Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments
reuters.com · Jun 29
Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?
investorplace.com · Jun 29
Lilly to Acquire Sigilon Therapeutics
prnewswire.com · Jun 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.